vs
LINKBANCORP, Inc.（LNKB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
LINKBANCORP, Inc.的季度营收约是REGENXBIO Inc.的1.5倍（$46.0M vs $30.3M），LINKBANCORP, Inc.净利率更高（6.4% vs -221.3%，领先227.7%），REGENXBIO Inc.同比增速更快（43.0% vs 7.3%），LINKBANCORP, Inc.自由现金流更多（$23.8M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 6.6%）
LINKBANCORP是一家总部位于美国的银行控股公司，主要为宾夕法尼亚州地区的个人消费者、小微企业和中型企业提供零售与商业银行服务，涵盖存款账户、贷款产品、财富管理解决方案及数字银行服务等核心业务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
LNKB vs RGNX — 直观对比
营收规模更大
LNKB
是对方的1.5倍
$30.3M
营收增速更快
RGNX
高出35.7%
7.3%
净利率更高
LNKB
高出227.7%
-221.3%
自由现金流更多
LNKB
多$76.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
6.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $46.0M | $30.3M |
| 净利润 | $2.9M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 8.5% | -190.0% |
| 净利率 | 6.4% | -221.3% |
| 营收同比 | 7.3% | 43.0% |
| 净利润同比 | -61.2% | -31.2% |
| 每股收益（稀释后） | $0.08 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LNKBRGNX
| Q4 25 | $46.0M | $30.3M | ||
| Q3 25 | $44.8M | $29.7M | ||
| Q2 25 | $42.3M | $21.4M | ||
| Q1 25 | $53.4M | $89.0M | ||
| Q4 24 | $42.9M | $21.2M | ||
| Q3 24 | $42.9M | $24.2M | ||
| Q2 24 | $41.3M | $22.3M | ||
| Q1 24 | $40.5M | $15.6M |
净利润LNKBRGNX
| Q4 25 | $2.9M | $-67.1M | ||
| Q3 25 | $7.8M | $-61.9M | ||
| Q2 25 | $7.4M | $-70.9M | ||
| Q1 25 | $15.3M | $6.1M | ||
| Q4 24 | $7.6M | $-51.2M | ||
| Q3 24 | $7.1M | $-59.6M | ||
| Q2 24 | $5.8M | $-53.0M | ||
| Q1 24 | $5.7M | $-63.3M |
毛利率LNKBRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率LNKBRGNX
| Q4 25 | 8.5% | -190.0% | ||
| Q3 25 | 22.3% | -176.3% | ||
| Q2 25 | 22.4% | -296.3% | ||
| Q1 25 | 36.0% | 13.6% | ||
| Q4 24 | 22.6% | -242.1% | ||
| Q3 24 | 21.3% | -256.6% | ||
| Q2 24 | 18.0% | -251.3% | ||
| Q1 24 | 18.1% | -408.8% |
净利率LNKBRGNX
| Q4 25 | 6.4% | -221.3% | ||
| Q3 25 | 17.5% | -208.3% | ||
| Q2 25 | 17.5% | -331.8% | ||
| Q1 25 | 28.7% | 6.8% | ||
| Q4 24 | 17.7% | -241.3% | ||
| Q3 24 | 16.5% | -246.3% | ||
| Q2 24 | 14.1% | -237.7% | ||
| Q1 24 | 14.1% | -405.4% |
每股收益（稀释后）LNKBRGNX
| Q4 25 | $0.08 | $-1.30 | ||
| Q3 25 | $0.21 | $-1.20 | ||
| Q2 25 | $0.20 | $-1.38 | ||
| Q1 25 | $0.41 | $0.12 | ||
| Q4 24 | $0.21 | $-0.99 | ||
| Q3 24 | $0.19 | $-1.17 | ||
| Q2 24 | $0.16 | $-1.05 | ||
| Q1 24 | $0.15 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $52.3M | $230.1M |
| 总债务越低越好 | $177.3M | — |
| 股东权益账面价值 | $306.4M | $102.7M |
| 总资产 | $3.1B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.58× | — |
8季度趋势，按日历期对齐
现金及短期投资LNKBRGNX
| Q4 25 | $52.3M | $230.1M | ||
| Q3 25 | $194.2M | $274.2M | ||
| Q2 25 | $155.1M | $323.3M | ||
| Q1 25 | $220.2M | $267.9M | ||
| Q4 24 | $166.1M | $234.7M | ||
| Q3 24 | $191.2M | $255.5M | ||
| Q2 24 | $181.7M | $290.4M | ||
| Q1 24 | $172.3M | $338.7M |
总债务LNKBRGNX
| Q4 25 | $177.3M | — | ||
| Q3 25 | $102.3M | — | ||
| Q2 25 | $102.3M | — | ||
| Q1 25 | $102.7M | — | ||
| Q4 24 | $112.5M | — | ||
| Q3 24 | $102.4M | — | ||
| Q2 24 | $102.3M | — | ||
| Q1 24 | $102.2M | — |
股东权益LNKBRGNX
| Q4 25 | $306.4M | $102.7M | ||
| Q3 25 | $305.5M | $161.5M | ||
| Q2 25 | $298.0M | $213.7M | ||
| Q1 25 | $294.1M | $274.2M | ||
| Q4 24 | $280.2M | $259.7M | ||
| Q3 24 | $277.4M | $301.4M | ||
| Q2 24 | $271.4M | $348.3M | ||
| Q1 24 | $268.2M | $390.7M |
总资产LNKBRGNX
| Q4 25 | $3.1B | $453.0M | ||
| Q3 25 | $3.1B | $525.2M | ||
| Q2 25 | $2.9B | $581.0M | ||
| Q1 25 | $2.9B | $490.9M | ||
| Q4 24 | $2.9B | $466.0M | ||
| Q3 24 | $2.9B | $519.1M | ||
| Q2 24 | $2.9B | $569.4M | ||
| Q1 24 | $2.8B | $629.2M |
负债/权益比LNKBRGNX
| Q4 25 | 0.58× | — | ||
| Q3 25 | 0.33× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.35× | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.38× | — | ||
| Q1 24 | 0.38× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $23.8M | $-52.8M |
| 自由现金流率自由现金流/营收 | 51.7% | -174.0% |
| 资本支出强度资本支出/营收 | 3.2% | 1.7% |
| 现金转化率经营现金流/净利润 | 8.59× | — |
| 过去12个月自由现金流最近4个季度 | $55.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流LNKBRGNX
| Q4 25 | $25.3M | $-52.3M | ||
| Q3 25 | $23.6M | $-56.0M | ||
| Q2 25 | $6.3M | $-49.3M | ||
| Q1 25 | $2.6M | $33.6M | ||
| Q4 24 | $25.4M | $-31.6M | ||
| Q3 24 | $14.0M | $-40.5M | ||
| Q2 24 | $6.4M | $-45.5M | ||
| Q1 24 | $-771.0K | $-55.5M |
自由现金流LNKBRGNX
| Q4 25 | $23.8M | $-52.8M | ||
| Q3 25 | $23.2M | $-56.5M | ||
| Q2 25 | $6.1M | $-49.7M | ||
| Q1 25 | $2.2M | $32.6M | ||
| Q4 24 | $22.6M | $-32.7M | ||
| Q3 24 | $13.1M | $-40.9M | ||
| Q2 24 | $6.3M | $-46.0M | ||
| Q1 24 | $-1.2M | $-56.0M |
自由现金流率LNKBRGNX
| Q4 25 | 51.7% | -174.0% | ||
| Q3 25 | 51.8% | -189.9% | ||
| Q2 25 | 14.5% | -232.8% | ||
| Q1 25 | 4.2% | 36.6% | ||
| Q4 24 | 52.6% | -154.2% | ||
| Q3 24 | 30.5% | -168.9% | ||
| Q2 24 | 15.3% | -206.2% | ||
| Q1 24 | -3.0% | -358.5% |
资本支出强度LNKBRGNX
| Q4 25 | 3.2% | 1.7% | ||
| Q3 25 | 0.8% | 1.7% | ||
| Q2 25 | 0.4% | 1.8% | ||
| Q1 25 | 0.7% | 1.2% | ||
| Q4 24 | 6.7% | 5.1% | ||
| Q3 24 | 2.1% | 1.3% | ||
| Q2 24 | 0.1% | 2.1% | ||
| Q1 24 | 1.1% | 3.6% |
现金转化率LNKBRGNX
| Q4 25 | 8.59× | — | ||
| Q3 25 | 3.01× | — | ||
| Q2 25 | 0.85× | — | ||
| Q1 25 | 0.17× | 5.53× | ||
| Q4 24 | 3.35× | — | ||
| Q3 24 | 1.97× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | -0.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LNKB
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
